Most people with Parkinson’s disease treated with SPN-830, an apomorphine infusion pump, report improvement in their health status. SPN-830 also reduced “off” time, when symptoms are not being adequately controlled, by an average of about three hours a day. That’s according to new results from an open-label…
The Michael J. Fox Foundation (MJFF) has awarded a $150,000 grant to a biopharmaceutical company seeking to develop a positron emission tomography (PET) tracer for NLRP3, a therapeutic target tied to brain inflammation in Parkinson’s disease. With the funding, Ventus Therapeutics hopes to identify and develop a…
Physiotherapy, and mind-body exercise particularly, can meaningfully ease motor symptoms of Parkinson’s disease, a recent meta-analysis of clinical trial data involving more than 2,500 people reported. Mind-body exercise refers to practices that focus on the connection between the body, breath, and the mind, such as yoga, tai chi, or…
People with Parkinson’s disease tend to report a poorer quality of life if their treatments cannot fully control nonmotor symptoms, which increase with disease duration and severity, a study reported. Findings highlight how important it is for clinicians to accurately identify and properly address nonmotor symptoms of Parkinson’s,…
Implanting electrodes into the brain triggers inflammation by activating a group of immune signaling proteins called the inflammasome — which detects infection and, in turn, prompts a strong inflammatory response, a new study shows. These findings may open new avenues to improve deep brain stimulation, a type of therapy used…
Sinopia Biosciences has selected SB-0110 as its lead clinical candidate for Parkinson’s disease after extensive preclinical studies. The move has triggered a cumulative funding of $3.3 million of its fast-track Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke. The fast-track SBIR…
The first healthy volunteer has been dosed in a clinical study that will test the safety and efficacy of Herantis Pharma’s HER-096 treatment candidate for Parkinson’s disease, the company announced in a press release. The Phase 1a clinical trial also is evaluating the ability of HER-096 to penetrate…
Medications to prevent nausea and vomiting usually are not necessary for Parkinson’s disease patients beginning treatment with Kynmobi (apomorphine hydrochloride), according to a recent analysis of Phase 3 clinical trial data. Nearly 90% of patients who did not use these medications were still able to achieve an optimal…
Measuring the length and density of nerves in the cornea — the clear outer layer of the eyeball — can help distinguish between motor subtypes of Parkinson’s disease, a new study suggests. The study, “The severity of corneal nerve loss differentiates motor subtypes in patients with…
Greater proportions of immune regulatory B-cells were associated with better motor performance in people with early Parkinson’s disease, a study revealed. Regulatory B-cell subsets may be protective by limiting pro-inflammatory responses that contribute to disease progression, data showed. Meanwhile, elevated levels of antibodies produced by regular B-cells against the…
Get regular updates to your inbox.
